Abstract
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) decreased cardiac events in large clinical trials; however, an understanding of the physiology driving this benefit is lacking. To investigate this, we measured micro- and macrovascular insulin sensitivity in 10 adults with T2DM before and after 12 weeks of EMPA 10 mg daily. We also measured endothelial function (FMD), peripheral and central aortic pressures, and skeletal (SM) and cardiac (CM) muscle microvascular perfusion (MBV- microvascular blood volume; MFV-microvascular flow velocity; MBF-microvascular blood flow) before and during a 120 min euglycemic insulin clamp at weeks 0 and 12. We hypothesized that EMPA would diminish micro- and macro-vascular insulin resistance and improve vascular function. At week 0, insulin infusion lowered peripheral SBP (132±6 vs 125±5, p<0.05) but diminished SM perfusion MBV (1.75±0.2 vs 1.29±0.1, p<0.01) MFV (0.08±0.01 vs 0.05±0.01, p<0.001) and MBF (0.14±3 vs 0.07±0.01, p<0.01). After 12 weeks of EMPA, insulin infusion improved FMD (7.6 ± 1.2 vs 8.7 ±1.6%, p <0.03), lowered peripheral SBP (127±6 vs 107±5, p<0.001); DBP (74±4 vs 65±3, p<0.04); MAP (92±3 vs 79±3, p<0.01); and PP (53±5 vs 42±3, p<0.05) as well as aortic SBP (117±5 vs 96±4, p<0.001); DBP (75±4 vs 66±3, p<0.03); MAP (89±3 vs 76±3, p<0.01); and PP (43±4 vs 30±2, p<0.01). In addition, EMPA improved SM perfusion (MBV: 1.29±0.1 vs 2.02±0.3, p<0.02; MFV: 0.05±0.01 vs 0.08±0.01, p<0.02; MBF: 0.07±0.01 vs 0.18±0.04, p<0.03) and CM perfusion (MBV: 4.51±0.6 vs 5.11±0.4, p=0.18; MFV: 0.37±0.04 vs 0.52±0.06, p<0.05; MBF: 1.80±0.4 vs 2.74±0.5, p<0.05). In conclusion, 12 weeks of EMPA in adults with T2D improved endothelial function (FMD), reduced central and peripheral blood pressures, and augmented SM and CM microvascular perfusion in response to insulin. These changes may contribute to the improved CV outcomes seen with SGLT2i therapy. Disclosure L.Jahn: None. L.Hartline: None. K.W.Aylor: None. W.B.Horton: None. E.Barrett: None. Funding National Institutes of Health (1R01HL142250-01A1)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
